Assessment and modulation of chemoresistance by different sub-groups of chemosensitizers in a NHL cell line model
Abstract
Background: The development of chemoresistance represents a major obstacle in the successful treatment of cancers such as Non-Hodgkin’s Lymphoma (NHL). With the recognition of important roles for both p53 and its more recently described paralog p73 in mediating the activity of anti-cancer drugs, there has been increasing recognition that cellular resistance to anthracyclines could and does arise through failure of p53 family member signalling. Despite these advances in understanding how cells respond to DNA damage in vitro, and how this is affected by molecular genetic changes which affect p53 family member signalling, the contribution of these to in vivo chemoresistance has not been definitively established. Our major task now is to determine how these changes operate individually and collectively in vivo to produce the phenotype of clinical chemoresistance, and how we can translate this knowledge into clinically useful strategies to improve the outcome of chemotherapy.Materials and Methods: In this study we used two cell lines derived from Nigerian patients with Burkitt's lymphoma in a suspension type cell culture. The reduction of the tetrazolium salt to a blue-black formazan product by living not by dead cells can be used to measure growth inhibitory effects (cell proliferation inhibitory) of tumor cells.Results: An alternative option for p53+ (resistant) cells is to use a PGP reversal agent in combination with DOX, but reducing the dose of DOX when combined with chemosensitizer.Conclusion: The altered cellular dose in chemoresistant cell lines may provide a rational basis for the use of modified anthracycline based regimens in chemosensitizers, preferably non-genotoxic, in the treatment of tumors expressing chemoresistance phenotype with p53 over-expression.Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. . Cancer. 1993;72(11 Suppl):3502-14.
Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: implications of the multidrug resistance gene. . Pharmacotherapy. 1993;13:88-109. .
Coley HM, Twentyman PR, Workman P. The efflux of anthracyclines in multidrug-resistant cell lines. Biochem Pharmacol. 1993;Oct 19;46(8):1317-26. .
Tsang WP, Chau SP, Fung KP, Kong SK, Kwok TT. Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells. Cancer Chemother Pharmacol. 2003;51:161-6.
Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene. 2002;Jul 11;21(30):4595-600.
Zalcenstein A, Stambolsky P, Weisz L, Muller M, Wallach D, Goncharov TM, et al. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene. 2003 Aug 28;22(36):5667-76.
El-Hizawi S, Lagowski JP, Kulesz-Martin M, Albor A. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer Res. 2002 Jun 1;62(11):3264-70.
Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000 May;25(1):47-54.
Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, et al. Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem. 2000 Sep 22;275(38):29503-12.
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003 Apr;3(4):387-402.
Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, et al. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene. 2003 Aug 14;22(34):5252-60.
Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, et al. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem. 2002 May 24;277(21):18817-26.
Pulvertaft JV. Cytology of Burkitt's Tumour (African Lymphoma). Lancet. 1964 Feb 1;1(7327):238-40.
Ngu VA. The African Lymphoma (Burkitt Tumour): Survivals Exceeding Two Years. Br J Cancer. 1965 Mar;19:101-7.
Evens AM, Gordon LI. Burkitt's and Burkitt-like lymphoma. Curr Treat Options Oncol. 2002 Aug;3(4):291-305.
Moro F, Ottaggio L, Bonatti S, Simili M, Miele M, Bozzo S, et al. p53 expression in normal versus transformed mammalian cells. Carcinogenesis. 1995 Oct;16(10):2435-40.
Hirokawa M, Kawabata Y, Miura AB. Dysregulation of apoptosis and a novel mechanism of defective apoptotic signal transduction in human B-cell neoplasms. Leuk Lymphoma. 2002 Feb;43(2):243-9.
Kawabata Y, Hirokawa M, Kitabayashi A, Horiuchi T, Kuroki J, Miura AB. Defective apoptotic signal transduction pathway downstream of caspase-3 in human B-lymphoma cells: A novel mechanism of nuclear apoptosis resistance. Blood. 1999 Nov 15;94(10):3523-30.
Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55-63.
Griffiths SD, Clarke AR, Healy LE, Ross G, Ford AM, Hooper ML, et al. Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene. 1997;14(5):523-31.
Goldenberg GJ, Wang H, Blair GW. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia. Cancer Res. 1986 Jun;46(6):2978-83.
Zhu C, Mills KD, Ferguson DO, Lee C, Manis J, Fleming J, et al. Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell. 2002 Jun 28;109(7):811-21.
Foroutan B, Ali Ruf A, Jerwood D, Anderson D. In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy. J Pharmacol Toxicol Methods. 2007 Jan-Feb;55(1):58-64.
Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 1993 Feb;8(2):307-18.
Wang JY, Prorok G, Vaughan WP. Cytotoxicity, DNA cross-linking, and DNA single-strand breaks induced by cyclophosphamide in a rat leukemia in vivo. Cancer Chemother Pharmacol. 1993;31(5):381-6.
Valenzuela MT, Nunez MI, Villalobos M, Siles E, Olea N, Pedraza V, et al. Relationship between doxorubicin cell sensitivity, drug-induced DNA double-strand breaks, glutathione content and P-glycoprotein in mammalian tumor cells. Anticancer Drugs. 1995;6(6):749-57.
Andre M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103(4):1222-8.
Dziegiel P, Jethon Z, Suder E, Sopel M, Rabczynski J, Surowiak P, et al. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat. Exp Toxicol Pathol. 2002 Feb;53(6):433-9.
Tham P, Dougherty W, Iatropoulos MJ, Gordon G, James VC, Hall C, et al. The effect of mitoxantrone treatment in beagle dogs previously treated with minimally cardiotoxic doses of doxorubicin. Am J Pathol. 1987 Jul;128(1):121-30.
Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011 May 13;145(4):571-83.
Files | ||
Issue | Vol 3 No 3&4 (2011) | |
Section | Original Articles | |
Keywords | ||
chemoresistance chemosensitizers NHL cell line model |
Rights and permissions | |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |